Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sana Biotechnology, Inc. (SANA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/21/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted allogeneic hypoimmune-modified islet cells evade rejection and control glucose without immunosuppression or insulin treatment in non-human primate diabetes study Data published in Science Translational Medicine, Natur..."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Investor presentation
Docs: "CAR 4 CD22 CD19 BCMA GPRC5D"
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year"
05/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/01/2023 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/16/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Announced SC291 IND clearance with goal to report initial clinical data this year"
03/15/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 4.8% stake in SANA BIOTECHNOLOGY INC
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies Goal is to report initial SC291 clinical data this year"
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies"
01/20/2023 SC 13G/A BAILLIE GIFFORD & CO reports a 5.6% stake in Sana Biotechnology, Inc.
01/10/2023 8-K Investor presentation
Docs: "Corporate Presentation"
11/29/2022 8-K Quarterly results
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy